Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16437905 | 0.81 | APLNR (0.35) | APLNRPTGDR2 | |
| SCHEMBL16437900 | 0.80 | APLNR (0.33) | APLNR | |
| SCHEMBL16437893 | 0.79 | USP28 (0.33) | MAPTPTGDR2 | |
| SCHEMBL16437904 | 0.78 | APLNR (0.32) | APLNR | |
| SCHEMBL16428498 | 0.77 | RAB9A (0.34) | APLNRPTGDR2 | |
| SCHEMBL22070791 | 0.72 | APLNR (0.39) | APLNRMAPT | |
| SCHEMBL16437902 | 0.72 | LMNA (0.35) | PTGDR2 | |
| SCHEMBL12980566 | 0.72 | APLNR (0.40) | APLNR | |
| SCHEMBL13172346 | 0.72 | APLNR (0.40) | APLNR | |
| SCHEMBL2881111 | 0.70 | APLNR (0.41) | APLNRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252059-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC (US) | 2015-09-10 | — | — | US | disclosed |
| US-9096615-B2 | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150038497-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC. | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252059-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | BACE1, BACE2, APP | APLNR 2808/4885MAPT 237/4885PTGDR2 1424/4885 |
| US-20150038497-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | BACE1, BACE2, APP | APLNR 2808/4885MAPT 237/4885PTGDR2 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.